[go: up one dir, main page]

CA2652549A1 - Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble - Google Patents

Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble Download PDF

Info

Publication number
CA2652549A1
CA2652549A1 CA002652549A CA2652549A CA2652549A1 CA 2652549 A1 CA2652549 A1 CA 2652549A1 CA 002652549 A CA002652549 A CA 002652549A CA 2652549 A CA2652549 A CA 2652549A CA 2652549 A1 CA2652549 A1 CA 2652549A1
Authority
CA
Canada
Prior art keywords
bmp
gdf
morphogenic protein
cdmp
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652549A
Other languages
English (en)
Inventor
Donald Engelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MARIEL THERAPEUTICS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2652549A1 publication Critical patent/CA2652549A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
CA002652549A 2006-05-17 2007-05-17 Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble Abandoned CA2652549A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80155106P 2006-05-17 2006-05-17
US60/801,551 2006-05-17
PCT/US2007/012202 WO2007142818A2 (fr) 2006-05-17 2007-05-17 Procédé pour traiter des défauts cartilagineux à l'aide d'un complexe de protéine morphogénique soluble

Publications (1)

Publication Number Publication Date
CA2652549A1 true CA2652549A1 (fr) 2007-12-13

Family

ID=38801965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652549A Abandoned CA2652549A1 (fr) 2006-05-17 2007-05-17 Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble

Country Status (6)

Country Link
US (2) US20090298761A1 (fr)
EP (2) EP2540310A1 (fr)
JP (3) JP5362554B2 (fr)
AU (1) AU2007257208B2 (fr)
CA (1) CA2652549A1 (fr)
WO (1) WO2007142818A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101300A1 (fr) * 2007-02-23 2008-08-28 Cellixe Pty Ltd Composition et méthode de traitement ou de prévention de troubles rachidiens
AU2010286314A1 (en) * 2009-08-25 2012-02-23 Cellixe Pty Ltd Composition and method for the treatment or prevention of spinal disorders III
WO2013033680A1 (fr) 2011-09-02 2013-03-07 Lifenet Health Peptides bmp & procédés d'utilisation
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
CA2901394A1 (fr) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Facteur de differenciation de croissance (gdf) destine au traitement d'insuffisance cardiaque diastolique
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2015073396A1 (fr) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Facteur de croissance et de différenciation (gdf) pour le traitement de l'insuffisance cardiaque diastolique
CA3010799A1 (fr) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Un traitement par le gdf11 previent la prise de poids, ameliore la tolerance au glucose, et diminue la steatose hepatique
US10743996B2 (en) * 2017-03-24 2020-08-18 Robert L. Bundy Amnion putty for cartilage repair

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5354557A (en) 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
CA2030518C (fr) 1989-03-28 2000-03-21 Elizabeth A. Wang Compositions osteoinductrices
ATE209251T1 (de) 1990-05-16 2001-12-15 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
ES2137931T3 (es) 1990-06-15 2000-01-01 Carnegie Inst Of Washington Proteinas gdf-1 y uog-1.
US6395883B1 (en) 1991-03-11 2002-05-28 Curis, Inc. Soluble morphogenic protein complex compositions of matter
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
WO1993016099A2 (fr) 1992-02-12 1993-08-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Sequences d'adn codant de nouveaux facteurs de croissance/differentiation
AU678380B2 (en) * 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof
WO1994010203A2 (fr) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Morphogenese induite par l'op-3
EP1439190A1 (fr) 1993-01-12 2004-07-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
JP3482207B2 (ja) 1993-01-12 2003-12-22 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−９
WO1994020539A1 (fr) * 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Procedes et compositions pour la production de proteines osteogenes recombinantes
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
EP1378572B1 (fr) 1993-05-12 2006-10-25 Genetics Institute, LLC Compositions contenant la BMP-11
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
AU697625B2 (en) 1993-07-09 1998-10-15 Johns Hopkins University School Of Medicine, The Growth differentiation factor-6
JPH09505991A (ja) 1993-10-08 1997-06-17 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子‐１０
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
EP0733109B9 (fr) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 et compositions de celles-ci pour l'induction de tendons
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
AU6267798A (en) * 1997-02-07 1998-08-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
EP0975752A1 (fr) * 1997-04-29 2000-02-02 Regeneron Pharmaceuticals, Inc. Proteine cerberus humaine
EP2309261A1 (fr) * 1997-05-30 2011-04-13 Stryker Corporation Procédés d'évaluation de la morphogénèse de tissus et activité
GB2327003A (en) * 1997-07-04 1999-01-06 Secr Defence Image data encoding system
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
ES2369629T3 (es) * 2004-05-25 2011-12-02 Stryker Corporation Uso de op-1 para tratar defectos del cartílago.
US20060194726A1 (en) * 2004-05-25 2006-08-31 Rueger David C Methods of treating cartilage defects
DE102005045338B4 (de) 2005-09-22 2009-04-02 Siltronic Ag Epitaxierte Siliciumscheibe und Verfahren zur Herstellung von epitaxierten Siliciumscheiben

Also Published As

Publication number Publication date
JP5362554B2 (ja) 2013-12-11
EP2540310A1 (fr) 2013-01-02
US20090298761A1 (en) 2009-12-03
WO2007142818A2 (fr) 2007-12-13
JP2009537555A (ja) 2009-10-29
JP2013049716A (ja) 2013-03-14
EP2035030A2 (fr) 2009-03-18
JP2016094488A (ja) 2016-05-26
US20150057222A1 (en) 2015-02-26
AU2007257208A1 (en) 2007-12-13
AU2007257208B2 (en) 2013-05-02
WO2007142818A3 (fr) 2008-03-27
AU2007257208A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
AU2007257208B2 (en) Use of a soluble morphogenic protein complex for treating cartilage defects
JP2016047855A (ja) 軟骨欠損を処置するための、形態形成タンパク質の使用
AU2008255016B2 (en) Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US20110177135A1 (en) Methods of treating cartilage defects
JP2001511042A (ja) マトリクスを含まない骨形成デバイス、移植片、およびその使用方法
JP2010527355A5 (fr)
US20130231284A1 (en) Methods of treating cartilage defects
AU2011265308B2 (en) Use of Morphogenic Proteins for Treating Cartilage Defects

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20160707